1,4-Dihydropyridine Calcium Channel Blockers Inhibit Plasma and LDL Oxidation and Formation of Oxidation-Specific Epitopes in the Arterial Wall and Prolong Survival in Stroke-Prone Spontaneously Hypertensive Rats
- 1 September 1999
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 30 (9) , 1907-1915
- https://doi.org/10.1161/01.str.30.9.1907
Abstract
Background and Purpose —Calcium-channel blockers (CCBs) reduce systolic blood pressure and stroke-related mortality in stroke-prone spontaneously hypertensive rats (SPSHR). Brain ischemia is associated with loss of intracellular antioxidants. Increased formation of oxygen radicals and oxidation of LDL may enhance arterial vasoconstriction by various mechanisms. CCBs that also exert antioxidative properties in vitro may therefore be particularly useful. To investigate such antioxidant effects in vivo, we determined several parameters of LDL oxidation in SPSHR treated with two 1,4-dihydropyridine–type (1,4-DHP) CCBs of different lipophilic properties and compared them with antioxidant-treated and untreated controls. We also tested whether these drugs decrease the formation of oxidation-specific epitopes in arteries. Methods —Five groups of 9 to 14 SPSHR each (aged 8 weeks) were treated with 80 mg/kg body wt per day nifedipine, 1 mg or 0.3 mg/kg body wt per day lacidipine, vitamin E (100 IU/d), or carrier for 5 weeks. A group of Wistar-Kyoto rats was used as normotensive control. Plasma samples were taken, and LDL was isolated by ultracentrifugation. Then LDL was exposed to oxygen radicals generated by xanthine/xanthine oxidase reaction (2 mmol/L xanthine+100 mU/mL xanthine oxidase), and several parameters of oxidation were determined. The presence of native apolipoprotein B and oxidation-specific epitopes in the carotid and middle cerebral arteries was determined immunocytochemically. Results —1,4-DHP CCBs completely prevented mortality. Normotensive Wistar-Kyoto rats showed less oxidation than control SPSHR. Plasma lipoperoxide levels were 0.87±0.27 μmol/L in control SPSHR, 0.69±0.19 and 0.63±0.20 μmol/L in the groups treated with 0.3 and 1 mg lacidipine, respectively, and 0.68±0.23 μmol/L in nifedipine-treated animals ( P P P Conclusions —In the SPSHR model, 1,4-DHP CCBs reduce plasma and LDL oxidation and formation of oxidation-specific epitopes and prolong survival independently of blood pressure modifications. Our results support the concept that the in vivo protective effect of these drugs on cerebral ischemia and stroke may in part result from inhibition of oxidative processes.Keywords
This publication has 37 references indexed in Scilit:
- The Classification of Calcium Antagonists and their Selection in the Treatment of HypertensionDrugs, 1998
- Effect of lacidipine on cholesterol esterification: in vivo and in vitro studiesBritish Journal of Pharmacology, 1997
- Safety of Nifedipine in Patients With HypertensionHypertension, 1997
- Effects of a Calcium Antagonist, Lacidipine, on Experimental Focal Cerebral Ischemia in RatsThe Japanese Journal of Pharmacology, 1997
- STROKE‐PRONE SHR AND ARTERIOLIPIDOSIS‐PRONE SHR AS MODELS FOR ATHEROSCLEROSIS: THEIR MECHANISMS AND APPLICATION FOR NUTRITIONAL AND PHARMACOLOGICAL STUDIESClinical and Experimental Pharmacology and Physiology, 1995
- Prooxidant iron and copper, with ferroxidase and xanthine oxidase activities in human atherosclerotic materialFEBS Letters, 1995
- Inhibition by Lacidipine of Salt-Dependent Cardiac Hypertrophy and Endothelin Gene Expression in Stroke-Prone Spontaneously Hypertensive RatsBiochemical and Biophysical Research Communications, 1995
- In Vitro Antioxidant Activity of Calcium Antagonists against LDL Oxidation Compared with α-TocopherolBiochemical and Biophysical Research Communications, 1994
- Partial resistance to anticoagulation after streptokinase treatment for acute myocardial infarctionThe American Journal of Cardiology, 1990
- Interaction of 1,4 dihydropyridine calcium channel antagonists with biological membranes: Lipid bilayer partitioning could occur before drug binding to receptorsJournal of Molecular and Cellular Cardiology, 1989